The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: ZEN-3694
DRUG: Testosterone cypionate
DRUG: Enzalutamide
DRUG: Luteinizing hormone-releasing hormone (LHRH) analogue

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]